DRUG · Unmapped registry intervention
Administration of CC-3
Find medicine records ·
Find other trials using this name
Clinical trial
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
NCT05999396
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedFIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Colorectal Cancerverified · MONDO: colorectal cancer
Breast Carcinomaverified · MONDO: breast carcinoma
Sarcomaverified · MONDO: sarcoma
Penile Carcinomaverified · MONDO: penile carcinoma
Interventions
Sponsors & collaborators
German Cancer Research Centerlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05999396 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.